Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mattias Udd"'
Autor:
Willie R. Earley, Koen Demyttenaere, Urban Gustafsson, Michael E. Thase, M.B.A. Hans Eriksson M.D., Mattias Udd
Publikováno v:
Depression and Anxiety. 29:574-586
Background A pooled analysis was performed on data from two studies evaluating the efficacy of once-daily extended-release quetiapine fumarate (quetiapine XR) monotherapy for patients with major depressive disorder. Through these analyses (based on H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be921d8a255b9e47a6a2b209e9de72a4
https://doi.org/10.1002/da.21970
https://doi.org/10.1002/da.21970
Autor:
P Wahlqvist, Liberty Fajutrao, Julie C. Locklear, Mattias Udd, Urban Gustafsson, Hans Eriksson
Publikováno v:
Journal of comparative effectiveness research. 3(4)
Aim: The aim was to evaluate the impact of quetiapine extended release (XR) on hospitalization length and cost in schizophrenia or bipolar disorder, versus quetiapine immediate release (IR), using Premier Perspective™ inpatient hospital database da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f0afe8f68f3198c45c9a91303118c4
https://pubmed.ncbi.nlm.nih.gov/25275231
https://pubmed.ncbi.nlm.nih.gov/25275231
Publikováno v:
Journal of affective disorders. 142(1-3)
Background To evaluate quetiapine in patients with bipolar I disorder with mixed symptoms. Methods : Data from 2 studies (D1447C00126, D1447C00127) were pooled and mixed events analyzed separately. Patients received quetiapine (400–800 mg/day) plus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d06dee475424bd9ae85d79c555245e3
https://pubmed.ncbi.nlm.nih.gov/23062763
https://pubmed.ncbi.nlm.nih.gov/23062763
Autor:
Michael E, Thase, Koen, Demyttenaere, Willie R, Earley, Urban, Gustafsson, Mattias, Udd, Hans, Eriksson
Publikováno v:
Depression and anxiety. 29(7)
A pooled analysis was performed on data from two studies evaluating the efficacy of once-daily extended-release quetiapine fumarate (quetiapine XR) monotherapy for patients with major depressive disorder. Through these analyses (based on Hamilton Rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6bedadf9247f5932750228d1f9b2d270
https://pubmed.ncbi.nlm.nih.gov/22753280
https://pubmed.ncbi.nlm.nih.gov/22753280
Autor:
P Wahlqvist, Mattias Udd, Liberty Fajutrao, Hans Eriksson, Urban Gustafsson, Julie C. Locklear
Publikováno v:
Value in Health. 14:A299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2abfb4fcb0baca98eae28fb8036fcc
https://doi.org/10.1016/j.jval.2011.08.370
https://doi.org/10.1016/j.jval.2011.08.370
Autor:
George I. Papakostas, Michael Bauer, Mattias Udd, Henrik Svedsater, Michael E. Thase, Stuart Montgomery, Hans Eriksson, Urban Gustafsson, Madhukar H. Trivedi
Publikováno v:
European Psychiatry. 25:1-1
ObjectivesEvaluate the effects of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) according to disease severity.MethodsPooled data (quetiapine XR 50, 150 and 300mg/day doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d734f50bf4a4d6cc73430994b392ba44
https://doi.org/10.1016/s0924-9338(10)71426-7
https://doi.org/10.1016/s0924-9338(10)71426-7